{"id":"direct-oral-anticoagulant","safety":{"commonSideEffects":[{"rate":"2-5%","effect":"Bleeding (major and minor)"},{"rate":"1-3%","effect":"Gastrointestinal bleeding"},{"rate":"0.3-0.8%","effect":"Intracranial hemorrhage"},{"rate":"5-15%","effect":"Dyspepsia"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:36:56.839696","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Direct oral anticoagulants (DOACs) work by directly inhibiting either Factor Xa or thrombin (Factor IIa) in the coagulation cascade, preventing the formation of fibrin clots. This class includes Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and direct thrombin inhibitors (dabigatran). By blocking these key enzymes, DOACs reduce thrombotic events while maintaining hemostasis.","oneSentence":"Direct oral anticoagulants inhibit specific clotting factors to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:56.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Acute coronary syndrome (in combination with antiplatelet therapy)"}]},"_fixedFields":["pubmed(2486)"],"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT07479147","phase":"","title":"SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-12-16","conditions":"Ischemic Stroke, Embolic Stroke of Undetermined Source, Patent Foramen Ovale (PFO)","enrollment":400},{"nctId":"NCT05198960","phase":"PHASE3","title":"AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2022-07-13","conditions":"Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis","enrollment":1308},{"nctId":"NCT05900388","phase":"","title":"A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-09-01","conditions":"Venous Thromboembolism, Children Under 2 Years","enrollment":850},{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT07288489","phase":"PHASE3","title":"Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.","status":"NOT_YET_RECRUITING","sponsor":"VarmX B.V.","startDate":"2026-03","conditions":"Blood Loss, Surgical, Coagulation Disorder","enrollment":800},{"nctId":"NCT07430748","phase":"EARLY_PHASE1","title":"REGENFAST vs L-PRF in Periodontal Regeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Santiago de Compostela","startDate":"2026-02-01","conditions":"Regeneration, Periodontal Defects, Biomaterials","enrollment":15},{"nctId":"NCT04874428","phase":"PHASE1","title":"Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-05-19","conditions":"Liver Cirrhosis","enrollment":24},{"nctId":"NCT06241677","phase":"NA","title":"Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-04-15","conditions":"CVA (Cerebrovascular Accident)","enrollment":260},{"nctId":"NCT05976685","phase":"NA","title":"Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-05-01","conditions":"Ischemic Stroke, Atrial Fibrillation","enrollment":482},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":"Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":12},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT06429332","phase":"PHASE4","title":"International Care Bundle Evaluation in Cerebral Hemorrhage Research","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-01-07","conditions":"Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage","enrollment":3500},{"nctId":"NCT07139314","phase":"NA","title":"Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-09-24","conditions":"Ischemic Stroke, Atrial Fibrillation","enrollment":240},{"nctId":"NCT07005024","phase":"PHASE3","title":"DOAC - Dosing Options in AntiCoagulation Prophylaxis","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2025-10-17","conditions":"Cancer, VTE (Venous Thromboembolism)","enrollment":996},{"nctId":"NCT07139301","phase":"NA","title":"Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-09-04","conditions":"Ischemic Stroke, Atrial Fibrillation","enrollment":438},{"nctId":"NCT07384013","phase":"NA","title":"Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2025-11-01","conditions":"Oncologic Diseases, Coagulation Defect, Pain Management","enrollment":30},{"nctId":"NCT07372170","phase":"","title":"Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients","status":"RECRUITING","sponsor":"Infanta Leonor University Hospital","startDate":"2025-12-01","conditions":"Antiphospholipid Syndrome (APS), Venous Thrombosis (Disorder), Thrombophilia","enrollment":600},{"nctId":"NCT06382584","phase":"","title":"Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-01-01","conditions":"Direct Oral Anticoagulants (DOACs), Femoral Fractures, Surgery","enrollment":610},{"nctId":"NCT07354230","phase":"PHASE4","title":"Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2022-01-11","conditions":"Atrial Fibrillation (AF)","enrollment":210},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT07119970","phase":"NA","title":"Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2025-12-09","conditions":"Myeloproliferative Neoplasm, Myeloproliferative Disorders","enrollment":300},{"nctId":"NCT07333144","phase":"","title":"Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-02-28","conditions":"Gastrointestinal Bleeding","enrollment":250},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT07309848","phase":"","title":"Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2025-11-01","conditions":"Blood Transfusion, Hip Fracture Surgeries, Geriatric","enrollment":374},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT06138184","phase":"NA","title":"Learning Theory Patient Education for Anticoagulants","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2026-04","conditions":"Knowledge, Attitudes, Practice","enrollment":68},{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT07185295","phase":"PHASE4","title":"Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Outcomes'10","startDate":"2024-10-18","conditions":"Anticoagulated Patients","enrollment":481},{"nctId":"NCT06954610","phase":"","title":"Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-11-04","conditions":"Ischemic Stroke, Atrial Fibrillation, Cerebrovascular Disorders","enrollment":500},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT04867837","phase":"PHASE3","title":"Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor","status":"RECRUITING","sponsor":"Octapharma","startDate":"2021-09-01","conditions":"Acute Major Bleeding","enrollment":260},{"nctId":"NCT02969746","phase":"PHASE4","title":"Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants","status":"WITHDRAWN","sponsor":"University Hospital, Angers","startDate":"2014-07-18","conditions":"Anticoagulants; Circulating, Hemorrhagic Disorder","enrollment":""},{"nctId":"NCT07208695","phase":"","title":"Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation","status":"NOT_YET_RECRUITING","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2025-10-01","conditions":"Oral Antiplatele, Anticoagulant Drugs, Lower Extremity Varicose Veins","enrollment":40},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT07012291","phase":"","title":"Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™","status":"RECRUITING","sponsor":"Perosphere Technologies Inc.","startDate":"2025-06-20","conditions":"Coagulation","enrollment":150},{"nctId":"NCT07173075","phase":"NA","title":"Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-10","conditions":"Direct Oral Anticoagulant, Hemmorhage, Elderly","enrollment":110},{"nctId":"NCT06517563","phase":"PHASE1","title":"Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-08-14","conditions":"Coagulation Disorder","enrollment":16},{"nctId":"NCT07159399","phase":"NA","title":"A Pharmacist-Led Education Program to Improve Adherence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation","status":"ENROLLING_BY_INVITATION","sponsor":"National Taiwan University","startDate":"2025-03-05","conditions":"Atrial Fibrillation (AF)","enrollment":400},{"nctId":"NCT06878066","phase":"PHASE3","title":"Thrombolysis in Factor Xa-inhibitors Trial","status":"RECRUITING","sponsor":"Guri Hagberg","startDate":"2025-03-14","conditions":"Stroke, Stroke (in Patients With Atrial Fibrillation), Ischemic Stroke","enrollment":300},{"nctId":"NCT06075628","phase":"","title":"Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","status":"RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2023-07-24","conditions":"Atrial Fibrillation, Ischemic Stroke, Acute","enrollment":100},{"nctId":"NCT06913595","phase":"PHASE1","title":"Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2024-03-25","conditions":"Deep Venous Thrombosis","enrollment":100},{"nctId":"NCT06696079","phase":"NA","title":"Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation","status":"RECRUITING","sponsor":"Rahul Raj","startDate":"2025-07-07","conditions":"Chronic Subdural Hematoma, Atrial Fibrillation (AF)","enrollment":332},{"nctId":"NCT07125417","phase":"PHASE4","title":"Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure","status":"RECRUITING","sponsor":"OCEAN-SHD Study Group","startDate":"2025-05-29","conditions":"Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy","enrollment":500},{"nctId":"NCT02066454","phase":"PHASE3","title":"Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2014-06-05","conditions":"Myeloma, Venous Thromboembolism","enrollment":108},{"nctId":"NCT07083609","phase":"","title":"Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam","status":"RECRUITING","sponsor":"Hieu Trung Dinh","startDate":"2025-07-11","conditions":"Cerebral Venous Thrombosis","enrollment":69},{"nctId":"NCT04276441","phase":"","title":"A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-02-25","conditions":"Atrial Fibrillation","enrollment":34244},{"nctId":"NCT03778502","phase":"","title":"DOAC in Unusual Site Venous Thrombosis","status":"COMPLETED","sponsor":"University of Malta","startDate":"2019-10-01","conditions":"Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis","enrollment":358},{"nctId":"NCT03686306","phase":"PHASE3","title":"VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rennes University Hospital","startDate":"2021-11-24","conditions":"Peripheral Artery Disease","enrollment":106},{"nctId":"NCT06884384","phase":"","title":"DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09-15","conditions":"Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events","enrollment":310},{"nctId":"NCT05687448","phase":"PHASE3","title":"DIrect Oral Anticoagulation and Bioprothesis Aortic Valve","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Aortic Valve Disease","enrollment":1500},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT06523959","phase":"PHASE4","title":"Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial","status":"RECRUITING","sponsor":"Clinical Urology and Epidemiology Working Group","startDate":"2024-06-06","conditions":"Venous Thromboembolism, Bleeding","enrollment":5436},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT03129490","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":11000},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT03630055","phase":"PHASE3","title":"Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-10-03","conditions":"Radial Artery Occlusion","enrollment":1800},{"nctId":"NCT03129555","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5000},{"nctId":"NCT06971081","phase":"NA","title":"LED Application Following Dental Extraction in Patients Taking Direct Oral Anticoagulants.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2023-08-17","conditions":"Direct Oral Anticoagulants (DOACs)","enrollment":50},{"nctId":"NCT06957366","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-01","conditions":"Atrial Fibrillation (AF), VTE","enrollment":920},{"nctId":"NCT05093504","phase":"NA","title":"Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)","status":"TERMINATED","sponsor":"CytoSorbents, Inc","startDate":"2021-12-27","conditions":"Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical","enrollment":9},{"nctId":"NCT05351749","phase":"NA","title":"Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan","startDate":"2022-08-01","conditions":"Pulmonary Embolism, Venous Thromboembolism, Atrial Fibrillation","enrollment":306},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT04394234","phase":"","title":"A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-05-15","conditions":"Uterine Hemorrhage","enrollment":961985},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06322953","phase":"PHASE3","title":"Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage","status":"RECRUITING","sponsor":"Walton Centre NHS Foundation Trust","startDate":"2025-03-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":1084},{"nctId":"NCT06571149","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-03-14","conditions":"Ischemic Stroke","enrollment":906},{"nctId":"NCT05333666","phase":"","title":"The Association Between Non-vitamin K Antagonist Oral Anticoagulant Concentration and Clinical Outcomes.","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-03-21","conditions":"Atrial Fibrillation","enrollment":1500},{"nctId":"NCT06887270","phase":"NA","title":"Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-09","conditions":"Anticoagulant-induced Bleeding, Direct Oral Anticoagulant, Cancer","enrollment":10},{"nctId":"NCT05627375","phase":"PHASE3","title":"Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-08-16","conditions":"Venous Thromboembolic Disease","enrollment":1400},{"nctId":"NCT06844227","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)","status":"RECRUITING","sponsor":"McMaster University","startDate":"2021-12-01","conditions":"Atrial Fibrillation (AF)","enrollment":1780},{"nctId":"NCT06862726","phase":"PHASE4","title":"Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation","status":"ENROLLING_BY_INVITATION","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2024-12-01","conditions":"Non Valvular Atrial Fibrillation","enrollment":120},{"nctId":"NCT05750680","phase":"","title":"DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-05-13","conditions":"Atrial Fibrillation, Thromboembolism, Venous","enrollment":23},{"nctId":"NCT03892824","phase":"NA","title":"Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Javelin Medical","startDate":"2019-04-15","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT06239402","phase":"","title":"Therapeutic Strategy with Direct Oral Anticoagulants and Antiaggregant Drugs in Ischemic Heart Disease","status":"COMPLETED","sponsor":"Istituti Clinici Scientifici Maugeri SpA","startDate":"2020-07-28","conditions":"Atrial Fibrillation","enrollment":394},{"nctId":"NCT06823466","phase":"","title":"Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants","status":"RECRUITING","sponsor":"University of L'Aquila","startDate":"2025-02-12","conditions":"Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF)","enrollment":200},{"nctId":"NCT05068414","phase":"","title":"Assessment of the Incidence of Hemorrhagic and Ischemic Events in Post-angioplasty in Anticoagulated Coronary Patients with Atrial Fibrillation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-04-12","conditions":"Atrial Fibrillation, Acute Coronary Syndrome, Thrombosis","enrollment":122},{"nctId":"NCT03243175","phase":"PHASE3","title":"Avoiding Anticoagulation After IntraCerebral Haemorrhage","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2019-01-17","conditions":"Intracerebral Hemorrhage, Atrial Fibrillation, Microhaemorrhage","enrollment":300},{"nctId":"NCT05378035","phase":"","title":"DOAC in Chinese Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-09-28","conditions":"Atrial Fibrillation, Stroke, Stroke, Acute","enrollment":427},{"nctId":"NCT06611319","phase":"PHASE3","title":"ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty","status":"RECRUITING","sponsor":"Prof. Stavros Konstantinides, MD","startDate":"2024-11-26","conditions":"Hip Arthroplasty, Total, Prevention of Venous Thromboembolism","enrollment":2932},{"nctId":"NCT03996772","phase":"PHASE3","title":"PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-06-03","conditions":"Atrial Fibrillation, Intracerebral Hemorrhage","enrollment":319},{"nctId":"NCT06739603","phase":"NA","title":"Impact of Renal Function Availability to Community Pharmacist for Dispensing Direct Oral Anticoagulant in Ambulatory Patients on Bleeding Occurrence","status":"NOT_YET_RECRUITING","sponsor":"Université de Reims Champagne-Ardenne","startDate":"2025-06-01","conditions":"AOD Prescription","enrollment":1920},{"nctId":"NCT06729034","phase":"PHASE2","title":"A Study of Direct Oral Anticoagulants in Patients with Painful Venous Malformations with Localized Intravascular Coagulation","status":"NOT_YET_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-02-01","conditions":"Venous Malformation, Low Flow, Anticoagulants","enrollment":20},{"nctId":"NCT06482333","phase":"NA","title":"Timing of Resumption of Direct Oral Anticoagulants Following Polypectomy","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-10-03","conditions":"Postpolypectomy Bleeding","enrollment":194},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT04565977","phase":"","title":"Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2020-07-01","conditions":"Hypercoagulable States","enrollment":42},{"nctId":"NCT06692504","phase":"","title":"Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2021-01-01","conditions":"Hemorrhage, Thrombosis, Anticoagulant Therapy","enrollment":2080},{"nctId":"NCT06372483","phase":"PHASE1","title":"Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-02-21","conditions":"Coagulation Disorder","enrollment":40},{"nctId":"NCT04865978","phase":"PHASE2","title":"Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices","status":"COMPLETED","sponsor":"Palak Shah","startDate":"2021-12-14","conditions":"Heart Failure","enrollment":30},{"nctId":"NCT06606275","phase":"","title":"The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis","status":"COMPLETED","sponsor":"Abu Dhabi Health Services Company","startDate":"2024-01-01","conditions":"End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)","enrollment":67},{"nctId":"NCT04979780","phase":"","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-07-20","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients","enrollment":3708},{"nctId":"NCT05028777","phase":"","title":"Cohort of Patients With Left Ventricular Thrombus: Management and Outcomes in the Direct Oral Anticoagulants Era","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-01-01","conditions":"Thrombus of Left Ventricle","enrollment":550},{"nctId":"NCT05955365","phase":"PHASE4","title":"Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-12-18","conditions":"Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation","enrollment":3010},{"nctId":"NCT03596502","phase":"","title":"Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-02-01","conditions":"Atrial Fibrillation, Ischemic Stroke, Systemic Embolization","enrollment":402764},{"nctId":"NCT05169242","phase":"NA","title":"A Trial on Prophylactic Clipping to Prevent Post-polypectomy Bleeding After Colonoscopy in Direct Oral Anticoagulant Users","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2021-12-15","conditions":"Post Polypectomy Bleeding","enrollment":584},{"nctId":"NCT04477837","phase":"","title":"Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2020-10-15","conditions":"Heavy Menstrual Bleeding","enrollment":84},{"nctId":"NCT04974684","phase":"NA","title":"DOT HeartMate 3 Study","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2022-04-01","conditions":"LVAD (Left Ventricular Assist Device) Thrombosis","enrollment":45},{"nctId":"NCT04660747","phase":"","title":"Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-01-27","conditions":"Cerebral Venous Thrombosis","enrollment":1300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2486,"recentPublications":[{"date":"2026 Mar 30","pmid":"41906919","title":"Early Versus Delayed Anticoagulation in Acute Ischaemic Stroke with Atrial Fibrillation According to Infarct Volume and Location: a Prespecified Subgroup Analysis of the OPTIMAS Randomised Controlled Trial.","journal":"International journal of stroke : official journal of the International Stroke Society"},{"date":"2026 Mar 27","pmid":"41889325","title":"Thrombolysis in Direct Oral Anticoagulant-Treated Stroke Patients: Cross-Sectional Survey of Canadian Practice.","journal":"The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques"},{"date":"2026 Mar 24","pmid":"41887551","title":"Timing of Direct Oral Anticoagulant Resumption After Outpatient Colonoscopy and Risk of Gastrointestinal Bleeding and Thromboembolic Events.","journal":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"},{"date":"2026 Jan-Dec","pmid":"41877615","title":"Discrepant Outcomes of Direct Oral Anticoagulant Trials in Device-Detected Atrial Fibrillation after Stroke: Insights from NOAH-AFNET 6 and ARTESIA.","journal":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis"},{"date":"2026 Mar 24","pmid":"41874642","title":"Population pharmacokinetics of rivaroxaban after transjugular intrahepatic portosystemic shunt.","journal":"European journal of clinical pharmacology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DOAC","low molecular weight heparin"],"phase":"phase_3","status":"active","brandName":"Direct oral anticoagulant","genericName":"Direct oral anticoagulant","companyName":"Centre Hospitalier Universitaire de Nīmes","companyId":"centre-hospitalier-universitaire-de-n-mes","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Direct oral anticoagulants inhibit specific clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Acute coronary syndrome (in combination with antiplatelet therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}